Phase II Study of CSL H1N1 Influenza Vaccine With and Without AS03 Adjuvant

Phase 2, randomised, double-blind trial of CSL H1N1 Pandemic Influenza Vaccine in influenza (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of safety laboratory adverse events at Day 29, Occurrence of vaccine-associated serious adverse events up to 12 months and 3 more. Status: withdrawn.